Lataa...
Nivo-lution in mesothelioma
The MERIT study was a single-arm, phase 2 clinical trial of nivolumab for the 2(nd) or 3(rd) line treatment of patients with malignant pleural mesothelioma in Japan. MERIT confirmed that PD-1 inhibition has activity in mesothelioma and led to the regulatory approval of nivolumab for the treatment of...
Tallennettuna:
| Julkaisussa: | Clin Cancer Res |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6744981/ https://ncbi.nlm.nih.gov/pubmed/31315884 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1836 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|